{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidu2wnmqzg3a4446y67zg5a2zd2u3cih33nntliatqjkk36dxax4e",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3miev2dcjgfh2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia7nvlkeaynhj3j3elxeuclzz2izofdfhn3qmxju7n6pgt2hu6spy"
    },
    "mimeType": "image/jpeg",
    "size": 760486
  },
  "path": "/news/2026-03-common-antidepressant-ease-covid-fatigue.html",
  "publishedAt": "2026-03-31T14:20:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A randomized clinical trial found that the antidepressant fluvoxamine significantly reduces long COVID-related fatigue, one of the condition's most persistent and debilitating symptoms, while the diabetes drug metformin showed no benefit. Patients taking fluvoxamine reported steadily improving fatigue and quality-of-life scores over 60 to 90 days, with fewer side effects than those on placebo. The findings are published in Annals of Internal Medicine.",
  "title": "Common antidepressant may ease long COVID fatigue"
}